Photoimmunotherapy for gastrointestinal cancer
Project/Area Number |
25462021
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Okayama University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
KAGAWA Shunsuke 岡山大学, 大学病院, 准教授 (00362971)
OYAMA Takanori 岡山大学, 大学病院, 助教 (10380164)
|
Co-Investigator(Renkei-kenkyūsha) |
FUJIWARA Toshiyoshi 岡山大学, 大学院医歯薬学総合研究科, 教授 (00304303)
TAZAWA Hiroshi 岡山大学, 大学病院, 助教 (90415513)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 光免疫療法 / HER2 / 腹膜播種 / アデノウイルス / 胃癌 / 近赤外線光線免疫療法 / 消化器癌 / 近赤外光線免疫療法 |
Outline of Final Research Achievements |
The lack of particular target antigens in gastric cancer other than HER2 has hampered the development of new treatments for gastric cancer.We hypothesized that HER2-extracellular domain (HER2-ECD) gene transduction combined with trastuzumab-based photoimmunotherapy (PIT) might provide excellent and selective antitumor effects for peritoneal dissemination of gastric cancer. Adenovirus/HER2-ECD(Ad/HER2-ECD) efficiently transduced HER2-ECD into HER2-negative gastric cancer cells. Trastuzumab-mediated PIT induced selective cell death of HER2-ECD-transduced tumor cells, even in heterogeneous gastric cancer cells.Anti-HER2 PIT integrated with adenoviral HER2-ECD gene transfer was applied in mice bearing peritoneal dissemination of HER2-negative gastric cancer. Intraperitoneal administration of Ad/HER2-ECD and Tra-IR700 with PIT inhibited peritoneal metastasis and prolonged the survival of mice. Molecular-targeted PIT integrated with gene transfer technology is a promising strategy.
|
Report
(4 results)
Research Products
(15 results)
-
-
-
-
-
[Journal Article] Viral transduction of HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2 negative breast cancer cells2015
Author(s)
Shimoyama K, Kagawa S, Ishida M, Watanabe S, Noma K, Takehara K, Tazawa H, Hashimoto Y, Tanabe S, Matsuoka J, Kobayashi H, Fujiwara T
-
Journal Title
Breast Cancer Res Treat
Volume: 149
Pages: 597-605
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
-
-
[Presentation] HER2抗原で修飾された癌細胞に対するTrastuzumabを用いた近赤外線光線免疫療法の効果2014
Author(s)
石田道拡, 香川俊輔, 下山京子, 竹原清人, 野間和広, 田澤 大, 黒田新士, 岸本浩行, 田邊俊介, 小林久隆, 藤原俊義
Organizer
第73回日本癌学会学術総会
Place of Presentation
神奈川県横浜市
Year and Date
2014-09-25
Related Report
-
-
-
-
-